Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$0.5 - $1.83 $403,250 - $1.48 Million
806,500 New
806,500 $1.32 Million
Q2 2023

Aug 11, 2023

SELL
$0.45 - $0.88 $340,439 - $665,748
-756,532 Reduced 75.07%
251,196 $136,000
Q1 2023

May 12, 2023

BUY
$0.82 - $1.33 $826,336 - $1.34 Million
1,007,728 New
1,007,728 $859,000
Q3 2022

Nov 14, 2022

BUY
$1.75 - $3.1 $547,911 - $970,585
313,092 New
313,092 $557,000
Q1 2022

May 16, 2022

SELL
$2.34 - $4.72 $85,300 - $172,058
-36,453 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.38 - $15.67 $159,664 - $571,218
36,453 New
36,453 $165,000
Q2 2021

Aug 16, 2021

SELL
$5.52 - $15.68 $3.15 Million - $8.95 Million
-570,857 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$1.66 - $15.81 $928,735 - $8.85 Million
559,479 Added 4917.2%
570,857 $3.88 Million
Q4 2020

Feb 16, 2021

BUY
$0.28 - $2.6 $3,185 - $29,582
11,378 New
11,378 $20,000

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $167M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.